Drug Profile
Natalizumab biosimilar - BioXpress Therapeutics
Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator BioXpress Therapeutics
- Class Anti-inflammatories; Antiepileptic drugs; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action Integrin alpha4beta1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in Switzerland (IV, Infusion)
- 22 Aug 2013 Preclinical trials in Multiple sclerosis in Switzerland (IV)